

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

**ANNOUNCEMENT**

**PROPOSED AMENDMENTS TO THE ARTICLES**

The Company is listed on the Hong Kong Stock Exchange (Listing Rules).

The Company is a public company listed on the Hong Kong Stock Exchange. The Company's articles of association are governed by the Companies Ordinance (Articles). The Company is a public company listed on the Hong Kong Stock Exchange.

The Board of Directors (Board) of the Company has proposed amendments to the Articles of Association (Proposed Amendments to the Articles).

On February 14, 2023, the State Council (State Council) of the PRC issued a decision (Decision) regarding the abolition of certain administrative regulations and documents (《國務院關於廢止部分行政法規和文件的決定》). The decision is effective from the date of its issuance. On February 17, 2023, the State Council issued a decision (Decision) regarding the special provisions for the overseas raising of shares and listing of joint stock companies (《國務院關於股份有限公司境外募集股份及上市的特別規定》). The decision is effective from the date of its issuance. On February 17, 2023, the State Council issued a decision (Decision) regarding the trial measures for the overseas issuance of securities and listing management of enterprises (《境內企業境外發行證券和上市管理試行辦法》). The decision is effective from the date of its issuance.

I a Ma da P C a L O a (《關於執  
行 到境外上市公司章程必備條款 的通知》). T D c a d T a M a  
(c c , **New PRC Regulations** ) a b c c Ma c 31, 2023.